When did APTOSE BIOSCIENCES INC (APTO) report earnings last quarter?
APTOSE BIOSCIENCES INC (APTO) last reported earnings on 3/28/2025.
NASDAQ:APTO • CA03835T4081
Past quarterly earnings results for APTOSE BIOSCIENCES INC (APTO), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2024 | -1.34 | -10.71 | 87.52% | 7.15% | - | - | ||
| Q3 2024 | -11.10 | -36.41 | 69.52% | -530.68% | - | - | ||
| Q2 2024 | -12.90 | -36.11 | 64.27% | -468.28% | - | - | ||
| Q1 2024 | -0.73 | -0.75 | 3.29% | 67.56% | - | - | ||
| Q4 2023 | -1.44 | -1.63 | 11.49% | 12.73% | - | - | ||
| Q3 2023 | -1.76 | -2.10 | 16.01% | -6.67% | - | - | ||
| Q2 2023 | -2.27 | -2.05 | -10.49% | -37.58% | - | - | ||
| Q1 2023 | -2.25 | -1.79 | -26.05% | -25.00% | - | - | ||
| Q4 2022 | -1.65 | -1.68 | 1.96% | -511.11% | - | - | ||
| Q3 2022 | -1.65 | -1.89 | 12.56% | -1,169.23% | - | - | ||
| Q2 2022 | -1.65 | -1.94 | 14.86% | -1,000.00% | - | - | ||
| Q1 2022 | -1.80 | -2.04 | 11.76% | -900.00% | - | - | ||
| Q4 2021 | -0.27 | -0.18 | -52.72% | -68.75% | - | - | ||
| Q3 2021 | -0.13 | -0.17 | 21.97% | 13.33% | - | - | ||
| Q2 2021 | -0.15 | -0.19 | 21.22% | 28.57% | - | - | ||
| Q1 2021 | -0.18 | -0.18 | -0.84% | -20.00% | - | - | ||
| Q4 2020 | -0.16 | -0.16 | 1.96% | - | - | - | ||
| Q3 2020 | -0.15 | -0.16 | 4.09% | - | - | - | ||
| Q2 2020 | -0.21 | -0.15 | -40.37% | - | - | - | ||
| Q1 2020 | -0.15 | -0.11 | -37.86% | - | - | - |
Notes
APTOSE BIOSCIENCES INC (APTO) last reported earnings on 3/28/2025.
APTOSE BIOSCIENCES INC (APTO) beat EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, APTOSE BIOSCIENCES INC (APTO) has beaten EPS estimates in 4 out of 4 releases.